Japanese

New Development in Osteoporosis Treatment. Updates of denosumab, anti-RANKL antibody for osteoporosis. Tokuyama Naoto 1 , Tanaka Sakae 2 1Graduate School of Medicine, Surgical Sciences, Orthopaedic Surgery, The University of Tokyo, Japan. 2Graduate School of Medicine, Surgical Sciences, Orthopaedic Surgery, The University of Tokyo, Japan. pp.85-91
Published Date 2013/12/28
DOI https://doi.org/10.20837/4201401085
  • Abstract
  • Look Inside
  • Reference

 Osteoporosis and osteoporosis-related fractures tend to increase year by year around the world including Japan. Denosumab, a fully human monoclonal antibody to receptor activator of NF-κB ligand(RANKL),a cytokine member of the TNF family essential for osteoclast differentiation has recently been approved in Japan, Europe and the US for the treatment of postomenopausal osteoporosis as well as bone metastasis. In some large clinical trials, denosumab significantly decreased bone resorption, increased bone mineral density(BMD),and reduced the risk of vertebral, nonvertebral and hip fractures in postmenopausal women. However, the mechanism of adverse events of denosumab, such as hypocalcemia and osteonecrosis of the jaws, has not been completely explained. Therefore, further knowledge should be accumulated by additional basic researches and clinical studies on denosumab.



基本情報

電子版ISSN 印刷版ISSN 0917-5857 医薬ジャーナル社

関連文献

もっと見る

文献を共有